[Home ] [Archive]    
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Subscription::
Contact us::
Site Facilities::
Webmail::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 14, Issue 4 (october & november 2009) ::
pajoohande 2009, 14(4): 225-231 Back to browse issues page
Surveying the efficacy of HyperCVAD regimen in acute lymphoblastic leukemia patients
Shirin Haghighi , Hamid Rezvani * , Hamid Attarian , Fatemeh Esfahani , Ladan Haghighi , Mojtaba Ghadiani , Habib Emami , Elham Maraghi
, hampejrad@yahoo.com
Abstract:   (14025 Views)
Background and Aim: Acute lymphoblastic leukemia (ALL) is a malignant disorder with the origin of B or T lymphocyte progenitor. This malignancy presents with anemia, thrombocytopenia and neutropenia due to suppression of hematopoiesis by increasing blast cells in bone marrow. With regard to many reports on effectiveness of HyperCVAD regimen in ALL patients and inadequate data from Iranian patients, the present study was conducted to assess the efficacy of this regimen in Iranian patients. Materials and Methods: This comparative before-after study included 36 adults with newly diagnosed ALL referred to Taleghani hospital between September 2004 and September 2007. Treatment consisted of four cycles of HyperCVAD alternating with four cycles of high dose methotrexate (MTX) and cytarabine with intrathecal prophylaxis and supportive care with antibiotic prophylaxis and G-CSF. Maintenance included 2 years of treatment with mercaptopurine, MTX, vincristine and prednisolone. Results of treatment on complete remission and survival were evaluated. Results: Mean age of patients was 21±11.3 years. Mature B-cell disease (Burkitt-type) was present in 2.7%, T-cell disease in 25%, and leukocytosis of more than 30×109/L, Philadelphia chromosome, and mediastinal mass were found in 27.8%, 8%, and 8% of patients, respectively. The complete response and mortality during induction were 91.6% and 2.7%, respectively, while estimated median survival time and estimated median CR duration were 13 and 8.3 months, respectively. Conclusion: Our results revealed that efficacy of HyperCVAD regimen in our patients were inferior to other studies. We recommend another study with larger sample size to compare the efficacy of this regimen with other standard regimens.
Keywords: Acute lymphocytic leukemia, HyperCVAD regimen, Malignany.
Full-Text [PDF 223 kb]   (3721 Downloads)    
Type of Study: Original | Subject: Medicine
Received: 2017 | Accepted: 2017 | Published: 2017
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shirin Haghighi, Hamid Rezvani, Hamid Attarian, Fatemeh Esfahani, Ladan Haghighi, Mojtaba Ghadiani, et al . Surveying the efficacy of HyperCVAD regimen in acute lymphoblastic leukemia patients. pajoohande 2009; 14 (4) :225-231
URL: http://pajoohande.sbmu.ac.ir/article-1-815-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 14, Issue 4 (october & november 2009) Back to browse issues page
Persian site map - English site map - Created in 0.03 seconds with 36 queries by YEKTAWEB 4712